TAI'AN, China, July 26, 2011 /PRNewswire-Asia-FirstCall/ --
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or
the "Company"), a leading plasma-based biopharmaceutical company in
China, today announced that
through its Guizhou Taibang subsidiary, it has donated its
life-saving plasma products (including 600 bottles 10-gram human
albumin, 250 bottles 2.5-gram human immunoglobulin for intravenous
injection, and 600 bottles 250IU human tetanus immunoglobulin) for
the passengers and crew members who were injured in the train
disaster near Wenzhou, Zhejiang
Province of China. The
donation was coordinated via the Wenzhou government officials and
organizations in charge of the accident. The market value of the
donation was close to RMB
600,000.
Mr. Chao Ming (Colin) Zhao, Chief
Executive Officer of China Biologic, said, "Right after we heard of
the tragedy, we immediately contacted the Ministry of Health and
the Zhejiang Provincial Health Department to offer our products. We
delivered our plasma shipment by express air for the injured
victims of the terrible train crash that occurred near Wenzhou on
July 23.
"These products are from our operations in Guizhou Province. We are fortunate to have a
good supply of plasma products that are essential to the hospitals
and surgical teams who are treating the injured. We thank the
citizens of Guizhou Province, who
have provided their valuable plasma to our company, for their
substantial contribution in helping the injured and saving lives in
the Wenzhou train accident.
"We extend our condolences to the families of the deceased and
wish a prompt recovery to the injured. Our hearts, minds, and
professional support are with you."
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and
its equity investment in Xi'an Huitian Blood Products Co., Ltd., is
currently one of the leading plasma-based biopharmaceutical
companies in China.
China Biologic is a fully integrated biologic products company
with plasma collection, production and manufacturing, research and
development, and commercial operations. The Company's plasma-based
biopharmaceutical products are irreplaceable during medical
emergencies and are used for the prevention and treatment of
various diseases. The Company sells its products to hospitals and
other healthcare facilities in China. Please see the Company's website at
www.chinabiologic.com for additional information.
Safe Harbor Statement
This news release may include forward-looking statements,
including all assumptions, expectations, predictions, intentions,
or beliefs about future events. Forward-looking statements can in
some cases be identified by the use of forward-looking terminology
such as "anticipates," "believes," "expects," "should," "will," or
similar expressions. Factors that could cause actual results to
differ materially from our forward-looking statements include our
potential inability to find alternative sources of plasma,
potential inability to increase production at permitted sites, and
potential additional regulatory restrictions on our operations. For
a description of additional risks and uncertainties that may cause
actual results to differ from the forward-looking statements
contained in this news release, please see our most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission ("SEC"), and our subsequent SEC filings. Copies of
filings made with the SEC are available through the Company's
website at www.chinabiologic.com and through SEC's website at
www.sec.gov. Future business decisions are subject to change and
the Company does not undertake to update the forward-looking
statements contained in this news release except as required by
law.
Company
Contact:
|
|
Mr. Y. Tristan
Kuo
|
|
Chief Financial
Officer
|
|
China Biologic Products,
Inc.
|
|
Tel:
+86-53-8620-2206
|
|
Email: IR@chinabiologic.com
|
|
www.chinabiologic.com
|
|
|
SOURCE China Biologic Products, Inc.